Publications

Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Other
• Patent
• Poster
• Report
• Scholarly edition
• Software
• Thesis dissertation
• Working paper

Filter by year:

Filter from 20262025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980 to Filter to 20262025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980

---

Search results

• Journal article
  Goodwin GM, Aaronson ST, Alvarez O, Carhart-Harris R, Chai-Rees J, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Kirlic N, Licht RW, Marwood L, Meyer TD, Mistry S, Nowakowska A, Páleníček T, Repantis D, Schoevers RA, Simmons H, Somers M, Teoh E, Tsai J, Wahba M, Williams S, Young AH, Young MB, Zisook S, Malievskaia Eet al., 2026,

  Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].

  , J Affect Disord, Vol: 393
  • Author Web Link
  • Cite
• Journal article
  Bailey NW, Hill AT, Godfrey K, Perera MPN, Rogasch NC, Fitzgibbon BM, Fitzgerald PBet al., 2025,

  EEG is better when cleaning effectively targets artifacts

  , CLINICAL NEUROPHYSIOLOGY, Vol: 180, ISSN: 1388-2457
  • Cite
  • Citations: 1
• Journal article
  Purple RJ, Gupta R, Thomas CW, Golden CT, Palomero-Gallagher N, Carhart-Harris R, Froudist-Walsh S, Jones MWet al., 2025,

  Correction: Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin.

  , Mol Psychiatry, Vol: 30
  • Author Web Link
  • Cite
• Journal article
  Hojlund M, Kafali HY, Kirmizi B, Fusar-Poli P, Correll CU, Cortese S, Sabe M, Fiedorowicz J, Saraf G, Zein J, Berk M, Husain MI, Rosenblat JD, Rubaiyat R, Corace K, Wong S, Hatcher S, Kaluzienski M, Yatham LN, Cipriani A, Gosling CJ, Carhart-Harris R, Tanuseputro P, Myran DT, Fabiano N, Moher D, Mayo LM, Nicholls SG, White T, De Prisco M, Radua J, Vieta E, Ladha KS, Katz J, Veroniki AA, Solmi Met al., 2025,

  Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis

  , EUROPEAN NEUROPSYCHOPHARMACOLOGY, Vol: 101, Pages: 41-55, ISSN: 0924-977X
  • Cite
• Journal article
  Alnagger NLN, Cardone P, Martial C, Perl YS, Mindlin I, Sitt JD, Roseman L, Carhart-harris R, Nutt D, Mallaroni P, Mason N, Ramaekers JG, Bonhomme V, Laureys S, Deco G, Gosseries O, Nunez P, Annen Jet al., 2025,

  A Virtual Clinical Trial of Psychedelics to Treat Patients With Disorders of Consciousness

  , ADVANCED SCIENCE
  • Cite
• Journal article
  Martens MAG, Cunha BG, Erritzoe D, Nutt D, Carhart-Harris R, Harmer CJet al., 2025,

  Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial.

  , Transl Psychiatry, Vol: 15

  Recent clinical trial data suggests that ratings on depression scales are lowered after psilocybin therapy compared to placebo, though it is unclear what neuropsychological mechanisms underpin these effects. This study compared psilocybin, with an established antidepressant, escitalopram, to investigate whether there are shared or distinct effects on emotional information processing. Patients with long-standing moderate-to-severe depression were randomly and double-blindly assigned in a 1:1 ratio to receive either 1) two doses of 25 mg of psilocybin, 3-weeks apart, plus 6-weeks of daily placebo (psilocybin group N = 30); or 2) two doses of 1 mg of psilocybin 3-weeks apart plus 6-weeks of daily oral escitalopram (escitalopram group N = 29); all patients received the same psychological support. Behavioural measures of affective bias as well as subjective measures of depression were collected at baseline and at the primary 6-week endpoint, using an established computerised task (Facial Emotion Recognition Task) and Quick Inventory of Depressive Symptomatology, respectively. Change in affective bias was further correlated with change in depression scores measured concurrently as well as at 1-month post-trial follow-up (week-10), corrected for baseline depression severity. Negative bias in facial expression recognition decreased after both treatments to a comparable level. Concurrently, change in negative affective bias was not associated with change in depression. Longitudinally, a decrease in the misclassification of positive faces as negative was associated with a decrease in depression scores at week-10 for the escitalopram group only. Therefore, a more positive behavioural bias in emotional processing was seen following psilocybin and citalopram compared to baseline. This highlights the potential for at least some overlap in cognitive mechanisms across two distinct treatments, which is noteworthy given the short dosing regim

  • Abstract
  • Author Web Link
  • Cite
• Journal article
  Shinozuka K, Jerotic K, Mediano P, Zhao AT, Preller KH, Carhart-Harris R, Kringelbach MLet al., 2025,

  Correction: Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology

  , Translational Psychiatry, Vol: 15, ISSN: 2158-3188

  Correction to: Translational Psychiatry https://doi.org/10.1038/s41398-024-03187-1, published online 04 December 2024The meta-analysis of the 11-dimensional Altered States of Consciousness (11D-ASC) included three studies that contained duplicated data from other papers: Duerler et al. (2021), Lewis et al. (2017), and Preller et al. (2017). When these studies are removed from the analysis, the results are generally similar to the previously reported findings. Out of 33 comparisons (3 doses x 11 dimensions) between LSD and psilocybin, one becomes insignificant (insightfulness, medium dose), while one becomes more significant (disembodiment, medium dose). Note that the 5D-ASC meta-analysis did not include any duplicates, hence the results of that meta-analysis are unaffected.We also wish to acknowledge two previous meta-analyses on the phenomenology of LSD and psilocybin, respectively, by Hirschfeld and colleagues:1. Hirschfeld, T., Prugger, J., Majic, T., Schmidt, T.T. Dose-response relationships of LSD-induced subjective experiences in humans (2023). Neuropsychopharmacology, 48, 1602-1611.2. Hirschfeld, T., Schmidt, T.T. Dose-response relationships of psilocybin-induced subjective experiences in humans (2021). Journal of Psychopharmacology. 35(4), 384-397.The original article has been corrected.

  • Abstract
  • Publisher Web Link
  • Cite
• Journal article
  Herrmann FM, Jones G, Low DM, Zech JM, Carhart-Harris RL, Kettner Het al., 2025,

  Exploring the potential psychological predictors associated with changes in depression, anxiety, and well-being following naturalistic psychedelic use

  , JOURNAL OF PSYCHIATRIC RESEARCH, Vol: 191, ISSN: 0022-3956
  • Cite
• Journal article
  Liardi A, Rosas FE, Carhart-Harris RL, Blackburne G, Bor D, Mediano PAMet al., 2025,

  Null models for comparing information decomposition across complex systems

  , PLOS COMPUTATIONAL BIOLOGY, Vol: 21, ISSN: 1553-734X
  • Cite
• Journal article
  Ertl N, Ashraf I, Azizi L, Roseman L, Erritzoe D, Nutt DJ, Carhart-Harris RL, Wall MBet al., 2025,

  Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects

  , NEUROPSYCHOPHARMACOLOGY, ISSN: 0893-133X
  • Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.